Vanta Bioscience Ltd Quarterly Results
Q4 FY22-23 Results Summary
Revenue
The revenue stands at ₹0.63 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 77.66 per cent from ₹2.82 crore. This corresponds to a year-on-year *(YoY) decline of 0.00 per cent.
Operating Profit
Operating Profit stands at ₹-1.30 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 136.36 per cent from ₹-0.55 crore. This corresponds to a year-on-year *(YoY) decline of 0.00 per cent.
PBDT
PBDT stands at ₹-1.56 crore, reflecting a quarter-on-quarter *(QoQ) increase of 48.34 per cent from ₹-3.02 crore. This corresponds to a year-on-year *(YoY) decline of 0.00 per cent.
Profit Before Tax
Profit Before Tax stands at ₹-1.61 crore, reflecting a quarter-on-quarter *(QoQ) increase of 62.82 per cent from ₹-4.33 crore. This corresponds to a year-on-year *(YoY) decline of 0.00 per cent.
Net Profit
Net Profit stands at ₹-1.60 crore, reflecting a quarter-on-quarter *(QoQ) increase of 63.80 per cent from ₹-4.42 crore. This represents a 0.00 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Vanta Bioscience Ltd Earnings
- YOY
- QOQ
Vanta Bioscience Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Vanta Bioscience Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Vanta Bioscience Ltd Financial Reports
Vanta Bioscience Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Transgene Biotek | 0.70% | -4.01% | 44.95% | 37.32% | -30.00% | -23.47% |
| Family Care | 0.00% | 0.00% | 22.90% | -3.88% | -24.94% | -30.60% |
| Global Longlife | -3.69% | -4.98% | 3.29% | -17.19% | -40.51% | -38.65% |
| Nexus Surgical | 2.90% | 7.97% | 28.51% | 21.32% | 19.08% | 38.07% |
| Dolphin Medical | 4.97% | 0.00% | 21.11% | 78.01% | 182.78% | 148.32% |
| Dr Lalchand. Lab | 2.81% | 1.86% | -29.78% | -43.80% | -40.37% | 11.51% |
| Gian Lifecare | 2.09% | 1.63% | 11.40% | -29.63% | -45.54% | -58.55% |
Company Info
Company Information
Managing Director : Dopesh Raja Mulakala
Independent Non Exe. Director : Padmanabhuni Venkata Appaji
Independent Non Exe. Director : Kathyayani Gonuguntla
Independent Non Exe. Director : Yogeswara Rao Danda
Company Sec. & Compli. Officer : Pooja Kothari